PCIBo — PCI Biotech Holding ASA Income Statement
0.000.00%
Last trade - 00:00
- NOK65.77m
- NOK35.71m
- NOK2.99m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9.39 | 7.37 | 6.27 | 4.75 | 2.99 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 98.2 | 89.5 | 92.3 | 61.2 | 25.2 |
Operating Profit | -88.8 | -82.1 | -86 | -56.4 | -22.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -88.7 | -72.2 | -88.4 | -55.1 | -20.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -88.7 | -72.2 | -88.4 | -55.1 | -20.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -88.7 | -72.2 | -88.4 | -55.1 | -20.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -88.7 | -72.2 | -88.4 | -55.1 | -20.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.38 | -1.94 | -2.37 | -1.32 | -0.544 |
Dividends per Share |